Lv41
520 积分 2021-12-10 加入
Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells
3小时前
已完结
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
11天前
已关闭
Targeting FAK in anticancer combination therapies
14天前
已完结
FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma
17天前
已完结
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
19天前
已完结
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
20天前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
21天前
已完结
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
21天前
已完结
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
21天前
已完结
根据血药浓度监测结果个性化调整舒尼替尼方案对转移性肾癌的安全性和疗效
22天前
已完结
皖公网安备34019202002308
